Cara Therapeutics/Vifor Pharma's Korsuva US Application In Pruritus Accepted For Review

The FDA has accepted Cara Therapeutics Inc's (NASDAQ: CARA) and its partner's Vifor Pharma GNHAF marketing application for Korsuva (difelikefalin) solution for injection for pruritus (or itch) in hemodialysis patients.
Under priority review status, the target action date is August 23.
The agency also stated that currently, it is not planning to hold an advisory committee for the application.
If approved, Korsuva injection would be the first therapy for the treatment of pruritus in hemodialysis patients.
Price Action: CARA shares are up 8.40% at $18.09 in the premarket trading on the last check Monday.

Posted In:

Biotech News Health Care Small Cap FDA General hemodialysis

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.